DOJ sub­poe­nas Bio­Marin over spon­sored test­ing pro­gram for rare dis­ease drugs

The De­part­ment of Jus­tice has is­sued a sub­poe­na to Bio­Marin over is­sues with its spon­sored test­ing pro­grams for two of its rare dis­ease drugs, the com­pa­ny dis­closed in an an­nu­al SEC fil­ing on Mon­day.

The sub­poe­na seeks doc­u­ments on Bio­Marin’s spon­sored test­ing pro­grams for Vimiz­im (elo­sul­fase al­fa), an en­zyme re­place­ment ther­a­py for the rare ge­net­ic dis­ease Morquio A syn­drome that af­fects the spine and some or­gans. It al­so re­quests doc­u­ments for its pro­gram for Naglazyme (gal­sul­fase), an­oth­er en­zyme re­place­ment ther­a­py for peo­ple with mu­copolysac­cha­ri­do­sis VI, a rare con­di­tion that can cause tis­sues and or­gans to at­ro­phy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER